Dynamics of Neutrophil Gelatinase Associated Lipocalin Serum in Malignant Subjects Treated with Chemotherapy

• Main Authors: Denny Moniaga, Syakib Bakri, Haerani Rasyid, Tutik Harjiyanti, Hasyim Kasim, Sahyudin Saleh, Muhammad Ilyas, Arifin Seweng
• Format: Article
• Language: English
• Published: Bulgarian Association of Young Surgeons 2019-01-01
• Series: International Journal of Medical Reviews and Case Reports
• Subjects: Neutrophil Gelatinase Associated Lipocalin; acute kidney injury; malignancy; chemotherapy
• Online Access: http://www.ejmanager.com/fulltextpdf.php?mno=19296

Background: Acute kidney injury in malignant subjects can be caused by the process of the malignant itself or its therapy, in this case chemotherapy. Neutrophil Gelatinase Associated Lipocalin detects acute renal injury earlier than creatinine. This study measure the dynamics of Neutrophil Gelatinase Associated Lipocalin serum in malignant subjects treated with chemotherapy. Method: Analytical research with cohort design. The research subjects were subjects aged > 18 years treated with chemotherapy at Dr Wahidin Sudirohusodo Hospital, Makassar, Indonesia. Serum level of Neutrophil Gelatinase Associated Lipocalin measured before and 24 hours after chemotherapy. Results: Post-chemotherapy Neutrophil Gelatinase Associated Lipocalin serum level was significantly higher than pre-chemotherapy (280,330 ng / ml vs. 204,453 ng / ml, p <0,001). The increased percentage of Neutrophil Gelatinase Associated Lipocalin serum level was significantly higher in subjects with serum creatinine level > 1.3 mg / dl compared to subjects with serum creatinine level < 1.3 mg / dl (185% vs 52%, p <0, 05). The increased percentage of Neutrophil Gelatinase Associated Lipocalin serum level was found to be higher in subjects with diabetes and / or hypertension than those without diabetes and / or hypertension (160% vs 48%, p <0.05). Discussion: This study found overall increased of Neutrophil Gelatinase Associated Lipocalin serum level in malignant patients 24 hours after chemotherapy, especially in patients with serum creatinine > 1.3 mg/dl and with diabetes and/or hypertension. Possible explanation is previous kidney injury, hypertension, and diabetes melitus makes kidney vulnerable to nephrotoxic substances.